Macroview Investment Management buys $14,069 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Macroview Investment Management scooped up 3 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 313 shares of Abbott Laboratories which is valued at $14,069.Abbott Laboratories makes up approximately 0.06% of Macroview Investment Management’s portfolio.

Other Hedge Funds, Including , Columbus Circle Investors sold out all of its stake in ABT during the most recent quarter. The investment firm sold 348,249 shares of ABT which is valued $15,653,793.Signaturefd boosted its stake in ABT in the latest quarter, The investment management firm added 874 additional shares and now holds a total of 5,270 shares of Abbott Laboratories which is valued at $235,833. Abbott Laboratories makes up approx 0.03% of Signaturefd’s portfolio.Edmp reduced its stake in ABT by selling 1,205 shares or 5.01% in the most recent quarter. The Hedge Fund company now holds 22,829 shares of ABT which is valued at $996,942. Abbott Laboratories makes up approx 0.94% of Edmp’s portfolio.Laurel Grove Capital reduced its stake in ABT by selling 12,800 shares or 29.96% in the most recent quarter. The Hedge Fund company now holds 29,925 shares of ABT which is valued at $1,291,862. Abbott Laboratories makes up approx 0.75% of Laurel Grove Capital’s portfolio.Pennsylvania Trust Co reduced its stake in ABT by selling 9,428 shares or 3.99% in the most recent quarter. The Hedge Fund company now holds 226,719 shares of ABT which is valued at $9,669,565. Abbott Laboratories makes up approx 0.76% of Pennsylvania Trust Co’s portfolio.

Abbott Laboratories closed down -0.24 points or -0.53% at $45.02 with 76,57,947 shares getting traded on Monday. Post opening the session at $45.06, the shares hit an intraday low of $44.88 and an intraday high of $45.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *